30 Apr 2025 (31 Days) Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
2 May 2024 Date | | 10.09 Cons. EPS | 9.55 EPS |
30 Apr 2025 (31 Days) Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
2 May 2024 Date | | 10.09 Cons. EPS | 9.55 EPS |
Biotechnology Industry | Healthcare Sector | Dr. Leonard S. Schleifer M.D., Ph.D. CEO | NASDAQ (NGS) Exchange | US75886F1075 ISIN |
US Country | 13,450 Employees | - Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.